Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 12/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 12/20 | 0.50 |
| ▸ | ITGAL | P20701 | 12/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201590 | 0.85 | ITGB2 (0.57) | ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL5201987 | 0.79 | ITGB2 (0.55) | ITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL4839726 | 0.79 | P2RX3 (0.35) | P2RX3KCNQ3KCNQ2PTGS2PTGS1 | |
| SCHEMBL5239341 | 0.78 | ITGAL (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL5204304 | 0.78 | ITGB2 (0.62) | ITGB2ICAM1ITGAL | |
| SCHEMBL7130481 | 0.78 | ITGB2 (0.62) | ITGB2ICAM1ITGAL | |
| SCHEMBL5203942 | 0.78 | ITGAL (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL5204347 | 0.76 | ITGB2 (0.56) | ITGB2ICAM1ITGALP2RX3MAPK1 | |
| SCHEMBL5200790 | 0.75 | ITGAL (0.58) | ITGB2ICAM1ITGAL | |
| SCHEMBL7706514 | 0.68 | ITGAL (0.60) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-6699888-B2 | ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | ICAM1, VCAM1, SELL | ITGB2 5/4885ICAM1 1/4885ITGAL 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.